In the present study, we have corroborated the immunophenotypic findings of van Rhenen et al (2007a,b) by confirming the possible aberrant expression of CLEC12A on the CD34+CD38− stem cell subset from MDS patients. The gene discussed is CD34; the disease is myelodysplastic syndrome.